Research Practice Sample Clauses

Research Practice. The Xxxxx Xxxxxx must ensure that research under the Project is conducted in compliance with all applicable laws and regulations and that all necessary licences and approvals have been obtained.
Sample 1Sample 2
AutoNDA by SimpleDocs
Research Practice. The Employing Institution must ensure that all the necessary legal and regulatory requirements in order to conduct the research are met and all the necessary licences and Ethical Committee approvals have been obtained. Where any part of the research is to be conducted outside the UK such legal and regulatory requirements, and such licences and approvals, should include those applicable in the additional countries involved. The Employing Institution must have in place formal written procedures for the handling of allegations of research misconduct and on request must make those available to Guts UK. The Xxxxx Xxxxxx or any other person working on the Grant Activities must carry out any animal research using the Grant in accordance with the appropriate Home Office licences and certificates which must remain valid. The Employing Institution must ensure that research involving animals gives due consideration to the refinement, reduction and replacement of animals in research and adheres to the principles in the NC3Rs “Responsibility in the Use of Animals in Bioscience Research”. Site visits may be made at any time subject to mutual agreement. Payment of the Grant will not commence until the Grant Budget, including salary details if covered and a breakdown of consumable and other miscellaneous costs, has been confirmed by the Employing Institution's Administrative Officer in the Admin Officer Letter. Guts UK will not cover any expenditure not stated in the Grant Budget. Conference travel expenses and publication costs will only be covered if allowed by the grant application guidelines published by Guts UK for the type of the project funded by the Grant. The Grant Budget in the Admin Officer Letter cannot include any items of expenditure which are disallowed in the grant application guidelines published by Guts UK for the type of project funded by the Grant. Xxxxx instalments are paid to the Employing Institution quarterly, in arrears, subject to receipt by Guts UK of an invoice. Quarterly invoices must state the start and end dates of the period covered by the invoice and provide a breakdown of costs incurred against the items of expenditure in the Grant Budget. All invoices must be submitted within 6 months of the end of the Grant Period. Guts UK will not pay the final claim until it has received the Final Report (see term 6.2) and is satisfied that the Grant Activities have been delivered in accordance with the Award Letter and any Special Conditions. Guts UK...
Sample 1Sample 2
Research Practice. 3.1. The Lead Applicant Institution and Lead Applicant shall ensure the Research; 3.1.1. is primarily relevant to the BactiVac Network and is compliant with ODA rules and regulations as set out by the OECD (guidance can be found at xxxxx://xxx.xxxx.xxx/files/legacy/international/gcrfodaguidance-pdf/); or 3.1.2. is primarily relevant to the BactiVac Network and demonstrates strong industry engagement; or 3.1.3. is primarily relevant to the BactiVac Network and is aligned to UK Health. 3.2. Prior to the commencement of the Research, the Lead Applicant and the Lead Applicant Institution will obtain any and all licences, consents and approvals (including ethical approval) necessary for the conduct of the Research and will continue to hold such licences, consents and approvals during the Duration. 3.3. Where any part of the Research is to be conducted outside the UK such legal and regulatory requirements, and such licences and approvals should include those applicable in the additional countries involved. 3.4. The Lead Applicant Institution must ensure that the requirements under the UK Policy Framework for Health and Social Care Research (or equivalent) are met for managing, monitoring and for research involving NHS patients, their organs, tissues or data and the necessary arrangement are in place with partner organisations. Where it also accepts the responsibilities of a Sponsor, (as defined in the UK Policy Framework for Health and Social Care Research), it must also ensure that the requirements of Sponsors are met. 3.5. The Lead Applicant Institution shall be responsible for managing and monitoring statutory requirements for which it accepts responsibility, for example, in relation to legislation of clinical trials, use of human organs, tissues and data. 3.6. For clinical studies involving human participants and/or patients, appropriate consent must be obtained. When collaborating with other laboratories, or where animal facilities are provided by third parties, researchers and the local ethics committee in the UK should satisfy themselves that welfare standards consistent with the principles of UK legislation (e.g. the Animals (Scientific Procedures) Act 1986) and set out in the guidance document 'Responsibility in the use of animals in bioscience research' (available at xxx.xx0xx.xxx.xx/xxxxxxxxxxxxxxxxx-xxxxxxx-xxxxxxxxxx-xxxxxxxx) are applied and maintained. 3.7. The Lead Applicant Institution is expected, wherever possible, to adopt procedures and tech...
Sample 1
Research Practice. 3.1 The Institution and the Grantholder will at all times during the continuance of the Agreement comply with: 3.1.1 the Policies; 3.1.2 the terms of the Agreement; and 3.1.3 any laws and regulations (as amended from time to time) applicable to the Project and the Agreement including human tissue legislation, health & safety legislation, the Data Protection Legislation and the Xxxxxxx Xxx 0000. 3.2 It is a condition of the Grant that the research undertaken in connection with the Project is conducted in accordance with best scientific and ethical practice. The Institution warrants that it has in place, and will continue to have in place through the Grant Period, formal written policies setting out the standards to be met in the conduct of research and the procedures to be followed following any allegation of research misconduct. 3.3 If at any time during or after the Grant Period, allegations of research misconduct are made in relation to the Project, or in relation to the Grantholder (or any other person involved in the Project) in connection with any other research, and are, in the reasonable opinion of Diabetes UK, substantiated, Diabetes UK reserves the right to take such steps as it, at its absolute discretion, considers appropriate which may include (but is not limited to): 3.3.1 Requiring the Institution to remove the Grantholder (or any other person involved in the Project) from the Project; 3.3.2 Requiring the Institution and/or Grantholder to retract published material; 3.3.3 withholding payment of subsequent instalments of the Grant, or requiring the Institution to reimburse Diabetes UK for some or all instalments of the Grant already paid; 3.3.4 taking such steps as it considers necessary to monitor the subsequent conduct of the Project and the Institution and the Grantholder will co-operate with Diabetes UK to facilitate this; 3.3.5 terminating the Grant with immediate effect. 3.4 The Institution and the Grantholder will conduct the Project in accordance with the principles set out in the Concordat to Support Research Integrity policy (xxxx://xxx.xxxxxxxxxxxxxx.xx.xx/highereducation/Documents/2012/TheConcordatToSupport ResearchIntegrity.pdf) 3.5 Prior to the commencement of the Project, the Grantholder and the Institution will obtain any and all licences, consents and approvals (including ethical approval) necessary to the conduct of the Project, will continue to hold such licences, consents and approvals during the Grant Period, and will prom...
Sample 1
Research Practice. 3.1. The Lead Applicant Institution and Lead Applicant shall ensure the Research; 3.1.1. is primarily for the benefit of Official Development Assistance (ODA) eligible countries as outlined in the Organisation for Economic Co-operation and Development (OECD) Development Co-Operation Directorate list (xxxxx://xxx.xxxx.xx.xx/documents/g3-nihr-oda-guidance-for- researchers/24953). ODA eligibility of the Research will be approved upon review of the Application Form. 3.1.2. is primarily relevant to the FAILSAFE PROJECT and GAMRIF and is compliant with ODA rules and regulations as set out by the OECD (xxxxx://xxx.xxxx.xx.xx/documents/g3-nihr-oda-guidance-for- researchers/24953); 3.1.3. is primarily relevant to the FAILSAFE PROJECT and demonstrates strong industry engagement. 3.2. The Lead Applicant and Lead Applicant Institution shall ensure the Grant is used solely for the delivery of the Research and must not, without the prior written consent of UoE make any material changes to the Research. 3.3. Prior to the commencement of the Research, the Lead Applicant and the Lead Applicant Institution will obtain any and all licences, consents and approvals (including ethical approval) necessary for the conduct of the Research and will continue to hold such licences, consents and approvals during the Duration. 3.4. The Grant must not be used to support activity which influences or attempts to influence Parliament, Government or political parties, to propagate a religion or belief, or to influence the awarding or renewal of contracts of grants, or to influence legislative or regulatory action. 3.5. The Lead Applicant must provide prior notification to UoE of any contact they may make directly with missions and or representatives of governments in relation to the promotion of the agreed objectives under this Grant through agreed meetings and reports. 3.6. Where, before or during the Duration, the Lead Applicant and the Lead Applicant Institution receives any funding from any other source or person towards the Research that was not already committed to the Lead Applicant Institution and disclosed to UoE, UoE may, where that funding duplicates funding of the Grant, require repayment of the Grant (up to the amount of duplicate funding received). 3.7. The Lead Applicant and the Lead Applicant Institution agrees and accepts that it will not apply for duplicate funding in respect of any part of the Grant for the Research or any related administration costs that UoE has provide...
Sample 1
Research Practice. The Institution and the Grantholder will at all times during the continuance of this Agreement comply with: the Policies; the terms of this Agreement; and any laws and regulations (as amended from time to time) applicable to the Project and this Agreement including human tissue legislation, health & safety legislation, the Data Protection Act 1998 and the Bribery Act 2010. It is a condition of the Grant that the research undertaken in connection with the Project is conducted in accordance with best scientific and ethical practice. The Institution warrants that it has in place, and will continue to have in place through the Grant Period, formal written policies setting out the standards to be met in the conduct of research and the procedures to be followed following any allegation of research misconduct. If at any time during or after the Grant Period, allegations of research misconduct are made in relation to the Grant, or in relation to the Grantholder in connection with any other research, and are, in the reasonable opinion of Diabetes UK, substantiated, Diabetes UK reserves the right to take such steps as it, at its absolute discretion, considers appropriate which may include (but is not limited to): Requiring the Institution to remove the Grantholder from the Project; Requiring the Institution and/or Grantholder to retract published material; withholding payment of subsequent instalments of the Grant, or requiring the Institution to reimburse Diabetes UK for some or all instalments of the Grant already paid; taking such steps as it considers necessary to monitor the subsequent conduct of the Project and the Institution and the Grantholder will co-operate with Diabetes UK to facilitate this; terminating the Grant with immediate effect. The Institution and the Grantholder will conduct the Project in accordance with the principles set out in the Concordat to Support Research Integrity policy (xxxx://xxx.xxxxxxxxxxxxxx.xx.xx/highereducation/Documents/2012/TheConcordatToSupportResearchIntegrity.pdf) The Grantholder and the Institution will comply with the terms of the policy on the use of animals in medical research (insert link to policy). Prior to the commencement of the Project, the Grantholder and the Institution will obtain any and all licences, consents and approvals (including ethical approval) necessary to the conduct of the Project, will continue to hold such licences, consents and approvals during the Grant Period, and will promptly upon request p...
Sample 1

Related to Research Practice

  • Research Program The term “Research Program” shall mean the research program to be undertaken by TSRI under the direction and control of the Principal Investigator as expressly set forth on Exhibit A hereto.

  • Research Project The findings of any research project, which would change the provisions of this Agreement will not be implemented until such changes are negotiated and agreed to by the parties.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Research Plan The Parties recognize that the Research Plan describes the collaborative research and development activities they will undertake and that interim research goals set forth in the Research Plan are good faith guidelines. Should events occur that require modification of these goals, then by mutual agreement the Parties can modify them through an amendment, according to Paragraph 13.6.

  • Research Use The Requester agrees that if access is approved, (1) the PI named in the DAR and (2) those named in the “Senior/Key Person Profile” section of the DAR, including the Information Technology Director and any trainee, employee, or contractor1 working on the proposed research project under the direct oversight of these individuals, shall become Approved Users of the requested dataset(s). Research use will occur solely in connection with the approved research project described in the DAR, which includes a 1-2 paragraph description of the proposed research (i.e., a Research Use Statement). Investigators interested in using Cloud Computing for data storage and analysis must request permission to use Cloud Computing in the DAR and identify the Cloud Service Provider (CSP) or providers and/or Private Cloud System (PCS) that they propose to use. They must also submit a Cloud Computing Use Statement as part of the DAR that describes the type of service and how it will be used to carry out the proposed research as described in the Research Use Statement. If the Approved Users plan to collaborate with investigators outside the Requester, the investigators at each external site must submit an independent DAR using the same project title and Research Use Statement, and if using the cloud, Cloud Computing Use Statement. New uses of these data outside those described in the DAR will require submission of a new DAR; modifications to the research project will require submission of an amendment to this application (e.g., adding or deleting Requester Collaborators from the Requester, adding datasets to an approved project). Access to the requested dataset(s) is granted for a period of one (1) year, with the option to renew access or close-out a project at the end of that year. Submitting Investigator(s), or their collaborators, who provided the data or samples used to generate controlled-access datasets subject to the NIH GDS Policy and who have Institutional Review Board (IRB) approval and who meet any other study specific terms of access, are exempt from the limitation on the scope of the research use as defined in the DAR.

  • Collaboration 31.1 If the Buyer has specified in the Order Form that it requires the Supplier to enter into a Collaboration Agreement, the Supplier must give the Buyer an executed Collaboration Agreement before the Start date. 31.2 In addition to any obligations under the Collaboration Agreement, the Supplier must: 31.2.1 work proactively and in good faith with each of the Buyer’s contractors 31.2.2 co-operate and share information with the Buyer’s contractors to enable the efficient operation of the Buyer’s ICT services and G-Cloud Services

  • Research Collaboration 3.7.1 Aarvik shall carry out the activities of each Work Item and deliver the required Data Package and/or deliverables in accordance with the applicable SOW. Without limiting the generality of the foregoing, Aarvik shall, in accordance with the applicable SOWs and the timeline approved by JRC, apply the Aarvik IP to (i) design and synthesize Collaboration Compounds, and (ii) by itself or through subcontractor(s), [***]. During the Research Term, if any Party identifies any Third Party Patent or Know-How that is necessary or reasonably useful for any activity under the SOWs but has not been included in the Aarvik IP, then such Party shall immediately inform the other Party and the Parties shall discuss in good faith the need of obtaining a license from such Third Party. 3.7.2 No later than [***] ([***]) days after completion of the [***], Aarvik shall, to the extent not already provided to ArriVent, deliver the Data Packages and all other deliverables required under the [***], as well as the results of the Patentability and FTO Analysis as described in Section 3.2.3, to ArriVent. ArriVent shall have the sole discretion to decide whether or not to advance any Collaboration Compound and which Collaboration Compound(s) will be advanced for further studies beyond the [***]. ArriVent shall inform Axxxxx of its decision in writing. If AxxxXxxx decides to advance the Collaboration Program to [***], ArriVent shall make the payment for the [***] pursuant to Section 6.2.1. 3.7.3 If, upon completion of the [***] for the Collaboration Program, AxxxXxxx decides not to advance the Collaboration Program to [***], ArriVent may terminate the Collaboration Program. If AxxxXxxx decides to advance the Collaboration Program to [***], ArriVent shall make the payment for the [***] pursuant to Section 6.2.1. 3.7.4 No later than [***] ([***]) days after completion of the [***], Aarvik shall, to the extent not already provided to ArriVent, deliver all Data Packages and deliverables required under the [***] to ArriVent. ArriVent shall have the sole discretion to decide whether or not to advance any Collaboration Compound and which Collaboration Compound(s) will be advanced for further studies beyond the [***]. ArriVent shall inform Axxxxx of its decision in writing. 3.7.5 No later than [***] ([***]) days after completion of the [***], Aarvik shall, to the extent not already provided to ArriVent, deliver all Data Packages and deliverables required under the [***] to ArriVent. 3.7.6 Within [***] ([***]) days after completion of the [***], Aarvik shall deliver to ArriVent a full report on all key results and findings of the Collaboration Program, and such other data, results and information as ArriVent may deem necessary for it to determine whether or not to exercise the Option (the “Full Report”).

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection xxxxx; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

  • Research Use Reporting To assure adherence to NIH GDS Policy, the PI agrees to provide annual Progress Updates as part of the annual Project Renewal or Project Close-out processes, prior to the expiration of the one (1) year data access period. The PI who is seeking Renewal or Close-out of a project agree to complete the appropriate online forms and provide specific information such as how the data have been used, including publications or presentations that resulted from the use of the requested dataset(s), a summary of any plans for future research use (if the PI is seeking renewal), any violations of the terms of access described within this Agreement and the implemented remediation, and information on any downstream intellectual property generated from the data. The PI also may include general comments regarding suggestions for improving the data access process in general. Information provided in the progress updates helps NIH evaluate program activities and may be considered by the NIH GDS governance committees as part of NIH’s effort to provide ongoing stewardship of data sharing activities subject to the NIH GDS Policy.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!